Travere Therapeutics (TVTX) Could Be 3% Undervalued As Russell Value Exits Stir Questions
Travere Therapeutics (TVTX) has been removed from several Russell value indices, prompting questions about its valuation. Despite this, the company has shown strong share price performance, with a 79.73% return over 90 days and a 289.73% return over one year. Simply Wall St indicates TVTX is about 3% undervalued based on one narrative, though its 9.9x P/S ratio suggests it looks expensive compared to a fair ratio of 8.1x and peer averages.
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
Travere Therapeutics announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application related to methods of using FILSPARI® (sparsentan) in IgA nephropathy. This patent is expected to provide U.S. coverage until October 2037 and will be listed in the FDA's "Orange Book." The company, which focuses on rare diseases, highlighted the importance of this intellectual property for its kidney disease treatment.
Is Travere Therapeutics (TVTX) Rebalancing Its Risk Profile With New Capital Tools And R&D Leadership Changes?
Travere Therapeutics recently experienced removal from Russell value and small-cap indices, filed a significant shelf registration for common stock, and announced upcoming changes in its R&D leadership. These developments prompt questions about how institutional ownership, funding flexibility, and execution risk will interact for the rare kidney disease-focused company, particularly concerning its key drug FILSPARI. While the changes don't alter near-term clinical catalysts for FILSPARI, they introduce considerations for liquidity and potential capital raising, especially amidst increasing competition in the rare kidney disease market.
Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 2000 Value Benchmark
Travere Therapeutics, Inc. (NasdaqGM: TVTX) has been removed from the Russell 2000 Value Benchmark. This news comes amidst other recent updates for the biopharmaceutical company, including favorable analyst assessments of its drug Filspari and executive changes. The company remains focused on developing treatments for rare kidney and metabolic diseases.
Understanding Momentum Shifts in (TVTX)
This article analyzes Travere Therapeutics Inc. (NASDAQ: TVTX) with an "Overweight Bias" due to strong sentiment across all time horizons. It highlights the absence of resistance levels above the current price, suggesting upside potential. The piece also details three AI-generated trading strategies and multi-timeframe signal analysis for TVTX.
Price to earnings forward of Travere Therapeutics, Inc. – NASDAQ:TVTX
This article provides financial information for Travere Therapeutics, Inc. (NASDAQ: TVTX), specifically focusing on its forward price-to-earnings ratio. It appears to be a stub or a data point from a financial platform like TradingView, indicating the period, value, and change for this metric.
Enterprise value to revenue forward of Travere Therapeutics, Inc. – NASDAQ:TVTX
The article provides the enterprise value to revenue forward for Travere Therapeutics, Inc. (NASDAQ: TVTX). It lists "Period," "Value," "Change," and "Change %" as key metrics related to this financial ratio. The information is presented within a TradingView interface, indicating its use for financial analysis and monitoring.
Enterprise value to EBITDA forward of Travere Therapeutics, Inc. – NASDAQ:TVTX
The article focuses on the enterprise value to EBITDA forward for Travere Therapeutics, Inc. (NASDAQ: TVTX). It appears to be a financial data page from TradingView, offering an overview of the company's financial metrics. The content itself seems to be a title with navigation and copyright information rather than a detailed analysis.
Enterprise value to EBIT forward of Travere Therapeutics, Inc. – NASDAQ:TVTX
The article discusses the enterprise value to EBIT forward for Travere Therapeutics, Inc. (NASDAQ: TVTX), a company in the Pharmaceuticals: Major sector. It appears to list financial data or an analysis of this metric, accessible on the TradingView platform.
Travere Therapeutics, Inc. Actuals & Estimates (NASDAQ:TVTX)
This article provides an overview of Travere Therapeutics, Inc. (NASDAQ: TVTX) stock, including its current price, market capitalization, historical highs and lows, and analyst forecasts. It also details the company's financial performance, such as earnings per share and revenue, and notes that Travere Therapeutics does not currently pay dividends. The report concludes with guidance on how to buy TVTX stock and available technical analysis.
TVTX Maintained by Guggenheim -- Price Target Raised to $65
Guggenheim analyst Vamil Divan maintained a 'Buy' rating for Travere Therapeutics (TVTX) and raised the price target to $65.00, reflecting confidence in the company's pipeline and future performance. Despite the positive analyst outlook, GuruFocus indicates that TVTX is significantly overvalued by 69.2% based on its GF Value™ of $34.88, and insider activity shows $16.5 million in recent share sales. The company has a GF Score™ of 70/100, driven by strong growth and momentum but tempered by challenges in profitability and valuation.
TVTX Forecast — Price Target — Prediction for 2027
This article provides an overview of Travere Therapeutics, Inc. (TVTX) stock, including its current price, analyst forecasts, and recent financial performance. Analysts predict a price range of $43.00 to $70.00 for TVTX, with a consensus price target of $57.71. The company has shown significant stock price growth over the past year and is scheduled to release its next earnings report on July 30, 2026.
Travere Therapeutics stock hits 52-week high at 56.9 USD
Travere Therapeutics (TVTX) stock reached a new 52-week high of $56.90, reflecting a 267% total return over the past year and a market capitalization of $5.26 billion. InvestingPro analysis suggests the stock is undervalued, and recent developments include positive Phase 3 study results for FILSPARI, a new collaboration agreement, and an analyst price target increase to $67. highlighting strong growth prospects.
Form 4 Travere Therapeutics Inc For: 22 June By Investing.com
This article from Investing.com announces the filing of Form 4 for Travere Therapeutics Inc. on June 22. It is a brief public notice about the regulatory filing, indicating an insider transaction or change in ownership, without providing details within the snippet. Viewers are invited to comment on the filing.
Form 4 Travere Therapeutics Inc For: 22 June By Investing.com
This article from Investing.com reports on a Form 4 filing by Travere Therapeutics Inc for June 22. It mentions the company's stock symbol TVTX and includes general market data for various indices and commodities. The article does not provide specific details about the content of the Form 4 filing.
Travere Therapeutics (NASDAQ: TVTX) CMO gifts 468 shares in Form 4
Travere Therapeutics' Chief Medical Officer, Jula Inrig, reported a bona fide gift of 468 shares of common stock to a donor-advised fund. This charitable transfer occurred on June 22, 2026, and was reported at $0.00 per share, indicating a non-market transaction. Following this gift, Inrig directly holds 112,770 shares of Travere Therapeutics common stock.
Travere Therapeutics Inc (TVTX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Travere Therapeutics Inc (TVTX), noting its current valuation score is 9.85, ranking 11th in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -246.62 and mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Travere Therapeutics Inc (TVTX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides an in-depth look into the shareholder structure of Travere Therapeutics Inc (TVTX), detailing its major shareholders and institutional holdings. It lists key investment firms and their respective proportions, along with a historical overview of institutional shareholding trends over several quarters. The report also includes recent changes in holdings by these major investors and related ETF exposures.
Travere Therapeutics Is Maintained at Buy by Citigroup
Citigroup has maintained its Buy rating for Travere Therapeutics (NASDAQ: TVTX). This indicates a continued positive outlook from the firm regarding the pharmaceutical company's stock.
[Form 4] Travere Therapeutics, Inc. Insider Trading Activity
Timothy Coughlin, a Director at Travere Therapeutics, engaged in an exercise-and-sell transaction involving 10,000 shares. He exercised stock options at $26.52 per share and subsequently sold these shares on the open market at a weighted average price of $50.0747 per share under a pre-established Rule 10b5-1 trading plan. After these transactions, Coughlin retains direct ownership of 56,250 common shares, indicating a routine liquidity event rather than a bearish signal.
Travere Therapeutics announces leadership changes in R&D By Investing.com
Travere Therapeutics announced leadership changes in its Research & Development division. Dr. William Rote, Chief Research Officer, will retire in February 2027 and Dr. Jula Inrig, current Chief Medical Officer, will expand her role to Executive Vice President, Head of Research and Development, and Chief Medical Officer. The company has seen significant growth following drug approvals during Dr. Rote's tenure and anticipates future profitability.
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
Travere Therapeutics announced that William Rote, Ph.D., its chief research officer, plans to retire in February 2027 after 10 years of service. Jula Inrig, M.D., the current chief medical officer, will expand her responsibilities to include the research organization and be named executive vice president, head of research and development and CMO. This transition recognizes Dr. Rote's significant contributions to the company's rare disease leadership and Dr. Inrig's instrumental role in advancing the pipeline and securing multiple rare kidney disease approvals.
Travere Therapeutics Announces Planned Retirement Of Chief Research Officer In 2027
Travere Therapeutics has announced that its Chief Research Officer will retire in 2027. The news was reported by Reuters and is less than a minute read.
[Form 4] Travere Therapeutics, Inc. Insider Trading Activity
Travere Therapeutics director Roy D. Baynes engaged in an options exercise and subsequent share sale in accordance with a pre-arranged Rule 10b5-1 trading plan. Baynes exercised options to acquire 4,500 shares at $21.38 per share and immediately sold these shares on the open market for $50.00 per share, totaling $225,000. Following these transactions, Roy D. Baynes directly owns 41,500 shares of Travere Therapeutics common stock.
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
Travere Therapeutics announced that its Chief Research Officer, William Rote, Ph.D., plans to retire in February 2027 after 10 years of service. Jula Inrig, M.D., currently the Chief Medical Officer, will expand her responsibilities to include the Company’s research organization and will be named executive vice president, head of research and development and CMO. Dr. Rote is recognized for his leadership in transforming the company into a leader in rare disease and guiding successful drug approvals, while Dr. Inrig is lauded for her scientific, strategic, and organizational leadership in advancing the company's pipeline.
Travere Therapeutics (TVTX) Is Up 10.5% After FILSPARI Shows Durable FSGS Benefit And Drives Non-GAAP Profitability – Has The Bull Case Changed?
Travere Therapeutics (TVTX) saw its stock rise by 10.5% after reporting durable proteinuria reductions for FILSPARI in FSGS and achieving its first non-GAAP profitable quarter. This performance strengthens FILSPARI's central role in the company's therapeutic and financial profile, reinforcing the investment narrative around its potential as a rare kidney disease treatment. Analysts previously had optimistic revenue and earnings forecasts, and this new data may further support a bullish outlook.
TVTX Maintained by Citigroup -- Price Target Raised to $70.00
Citigroup has maintained a "Buy" rating for Travere Therapeutics (TVTX) and raised its price target to $70.00, reflecting confidence in the company's therapies for rare kidney and metabolic diseases. Despite this positive outlook, GuruFocus indicates that TVTX is currently overvalued by 54.9% based on its GF Value™ of $34.53, and recent insider activity shows significant selling of $16.0 million in shares. The stock has a GF Score™ of 70/100, showing strong growth and momentum but weaker financial strength and profitability.
Travere Therapeutics (TVTX) Is Up 10.5% After FILSPARI Shows Durable FSGS Benefit And Drives Non-GAAP Profitability – Has The Bull Case Changed?
Travere Therapeutics' stock surged 10.5% after FILSPARI demonstrated durable benefits in focal segmental glomerulosclerosis (FSGS) and the company achieved its first non-GAAP profitable quarter, primarily driven by the drug's commercial success. This combination of sustained clinical efficacy and early profitability strengthens FILSPARI's role in Travere's financial and therapeutic strategy. The article explores how these developments might alter the investment outlook for TVTX, especially considering analysts' already optimistic forecasts and the drug's safety profile.
Travere Therapeutics (TVTX) Is Up 10.5% After FILSPARI Shows Durable FSGS Benefit And Drives Non-GAAP Profitability – Has The Bull Case Changed?
Travere Therapeutics (TVTX) saw its stock rise by 10.5% after reporting long-term Phase 3 DUPLEX data for its drug FILSPARI, showing durable benefits in focal segmental glomerulosclerosis (FSGS) and strong tolerability for up to five years. The company also announced its first non-GAAP profitable quarter, primarily driven by FILSPARI's commercial success. This new data and financial performance suggest a strengthening investment narrative for Travere, with analysts projecting significant revenue and earnings growth for the company through 2029.
TVTX Financials: Revenue Breakdown, Margins & Competitor Comparison
The article analyzes Travere Therapeutics Inc.'s (TVTX) financial performance, highlighting its revenue streams, profitability margins, and market position. TVTX's primary revenue driver is FILSPARI, contributing 84.5% of total sales, with a gross margin of 98.47%. Despite high gross margins, the company reported negative operating, net margins, and ROE, indicating challenges in converting operations to shareholder value, and is compared against competitors AMRX and INDV.
Roy Baynes to sell 4,500 TVTX shares via option exercise (TVTX)
Roy Baynes has filed a Form 144 notice to sell 4,500 shares of Travere Therapeutics, Inc. (TVTX) common stock through a stock option exercise scheduled for June 12, 2026. The sale will be executed via Morgan Stanley Smith Barney LLC Executive Financial Services, with cash as the planned method of payment. This filing is a routine regulatory notice and follows several prior sales by Baynes between April and May 2026.
TVTX (NASDAQ: TVTX) Form 144 reports 3,250-share sale
Travere Therapeutics, Inc. (NASDAQ: TVTX) has filed a Form 144, indicating an intended sale of up to 10,000 shares and disclosing a previous sale of 3,250 common shares on May 15, 2026. This sale generated proceeds of $141,182.59 and was facilitated by Wells Fargo Clearing Services. The filing also notes that the securities involved were stock options originally dated May 9, 2018.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics announced on June 11, 2026, that its Board of Directors' Compensation Committee granted inducement equity awards to six new employees. These grants consist of 32,000 restricted stock units (RSUs) and were made outside the company's 2018 Equity Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, dependent on continued employment.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics announced inducement equity grants to six new employees on June 10, 2026, consisting of 32,000 restricted stock units (RSUs). These grants were made under Nasdaq Listing Rule 5635(c)(4) as material inducements for employment and will vest over four years.
Travere Therapeutics (TVTX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
Travere Therapeutics (TVTX) presented at the Goldman Sachs 47th Annual Global Healthcare Conference 2026, highlighting its focus on rare kidney diseases with FILSPARI for IgA nephropathy and FSGS, and a new BTK inhibitor for immune-driven kidney diseases. The company emphasized FILSPARI's durable efficacy and market positioning as the first approved therapy for FSGS, anticipating its foundational role in future combination therapies. Recent expansion includes the licensing of civorebrutinib and strong sales growth driven by FILSPARI's FDA approvals.
Travere Therapeutics stock hits 52-week high at 48.7 USD
Travere Therapeutics (TVTX) stock recently hit a 52-week high of $48.70, reflecting a 216% increase over the past year. The company, with a $4.45 billion market cap and 96% revenue growth, is projected to become profitable this year with expected earnings of $1.75 per share, and analysts consider it undervalued. Recent positive developments include long-term clinical trial results for FILSPARI, a raised price target from H.C. Wainwright, and a new licensing agreement for civorebrutinib.
3 Stocks That May Be Priced Below Their Estimated Value In June 2026
This article identifies three U.S. stocks—Travere Therapeutics (TVTX), Goosehead Insurance (GSHD), and National Bank Holdings (NBHC)—that appear to be undervalued based on discounted cash flow analysis as of June 2026. Despite market drops, these companies show strong revenue or earnings growth potential, with projected discounts to their fair value. The analysis suggests these stocks could offer opportunities for investors seeking future growth.
Travere Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
This article provides the transcript of Travere Therapeutics Inc's appearance at the Goldman Sachs Healthcare Conference. Eric Dube, President and CEO of Travere Therapeutics, discusses the company's background, focusing on its rare kidney disease commercial footprint, and answers questions from Goldman Sachs' Christina Yoon. The transcript highlights Travere's current activities and its emphasis on rare disease therapies.
Travere therapeutics CCO sells $101,417 in stock for tax obligations
Peter Heerma, Chief Commercial Officer at Travere Therapeutics, sold 2,174 shares of common stock for $101,417 to cover tax obligations related to the vesting of performance restricted stock units. This transaction was not a discretionary trade but a mandatory "sell to cover." Following the vesting of 4,250 shares and the sale, Mr. Heerma now directly holds 140,684 shares of Travere Therapeutics.
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
Everest Medicines announced an exclusive licensing and collaboration agreement with Travere Therapeutics for civorebrutinib, a potential best-in-class BTK inhibitor for rare kidney diseases. Everest will receive an upfront payment of $112.5 million and is eligible for up to approximately $1.03 billion in additional payments tied to developmental, regulatory, and commercial milestones. This partnership aims to accelerate the global development and commercialization of civorebrutinib, expanding its value in autoimmune kidney diseases and providing innovative treatment options for over 10 million affected patients globally.
Travere Therapeutics, Everest Medicines Partner to Advance Civorebrutinib
Travere Therapeutics has entered into an exclusive licensing agreement with Everest Medicines to acquire rights for civorebrutinib, an experimental treatment for rare immune-mediated kidney diseases, in most markets outside China and certain Asian regions. The deal involves an upfront payment of $112.5 million to Everest, with potential for an additional $1.03 billion in milestone payments, and aims to expand Travere's nephrology pipeline while providing Everest with a global development partner. Civorebrutinib, an oral Bruton’s tyrosine kinase inhibitor, is intended for conditions like primary membranous nephropathy, immune-mediated focal segmental glomerulosclerosis, and minimal change disease.
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
Travere Therapeutics announced long-term positive results from the open-label extension of the Phase 3 DUPLEX Study for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS). The data presented at the ERA 2026 Congress showed sustained and deepened reductions in proteinuria for patients on FILSPARI, including those who transitioned from irbesartan, with a safety profile consistent with previous findings. These results reinforce FILSPARI's potential as a foundational treatment for FSGS.
Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines
Travere Therapeutics has secured global development and commercialization rights for civorebrutinib, an investigational oral BTK inhibitor, from Everest Medicines for $1.14 billion. This partnership aims to advance civorebrutinib for various rare immune-mediated kidney diseases, including primary membranous nephropathy, FSGS, and minimal change disease. The agreement includes an upfront payment of $112.5 million and up to $1.03 billion in potential milestone payments for Everest Medicines, alongside tiered royalties.
Everest Medicines signs $1 B deal with Travere Therapeutics for rare kidney diseases treatment
Everest Medicines has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics for civorebrutinib, an investigational oral BTK inhibitor for rare, immune-mediated kidney diseases. The deal is valued at up to $1.14 billion, including an upfront payment of $112.5 million and potential milestone payments. Travere will develop and commercialize civorebrutinib in markets outside China and certain East and Southeast Asian countries.
Everest Medicines signs $1 B deal with Travere Therapeutics for rare kidney diseases treatment
Everest Medicines has secured an exclusive licensing and collaboration agreement with Travere Therapeutics for civorebrutinib, a potential best-in-class oral BTK inhibitor. The deal, valued at up to $1.03 billion in milestones plus an upfront payment of $112.5 million, focuses on developing and commercializing the treatment for rare, immune-mediated kidney diseases in markets outside China and certain East and Southeast Asian countries. Civorebrutinib holds promise for conditions like primary membranous nephropathy, focal segmental glomerulosclerosis, and minimal change disease, addressing significant unmet medical needs.
TVTX Maintained by Citigroup -- Price Target Raised to $62
Citigroup has reiterated a 'Buy' rating for Travere Therapeutics (TVTX) and increased its price target from $59.00 to $62.00, signaling a positive outlook based on pipeline developments. Despite this, GuruFocus indicates TVTX is currently 32.8% overvalued with a high forward P/E ratio, and recent insider selling activity suggests caution for investors. Strengths lie in growth and momentum, but financial strength and profitability are areas of concern.
Travere inks licensing deal worth up to $1.1B with China’s Everest Medicines
Travere Therapeutics has signed a licensing agreement with China's Everest Medicines for the rights to develop and commercialize their kidney disease drug, sparsentan, in Greater China, South Korea, and Southeast Asia. The deal includes an upfront payment of $48 million, potential milestone payments up to $1.066 billion, and royalties on net sales. This partnership aims to expand the global reach of sparsentan, which has already received accelerated approval in the U.S. for IgA nephropathy.
TVTX Reiterated by Wedbush -- Price Target Maintained at $55
Wedbush has reiterated an 'Outperform' rating for Travere Therapeutics (TVTX), maintaining a price target of $55.00, reflecting confidence in the company's growth potential. While analysts view TVTX positively, GuruFocus indicates the stock is currently overvalued by 26.2% based on its GF Value, and recent insider selling raises concerns for potential investors. Despite strong growth and momentum scores, its financial strength and profitability ratings are low, advising caution.
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Everest Medicines has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics for civorebrutinib, an investigational oral BTK inhibitor. This agreement grants Travere development and commercialization rights outside of China and certain East and Southeast Asian countries. The deal includes an upfront payment of $112.5 million to Everest, with potential for an additional $1.03 billion in milestone payments and tiered royalties, aiming to advance civorebrutinib as a potential best-in-class treatment for rare, immune-mediated kidney diseases like primary membranous nephropathy, FSGS, and minimal change disease.
Travere Therapeutics signs license deal with Everest Medicines for BTK inhibitor
Travere Therapeutics has entered into an exclusive licensing agreement with Everest Medicines for the development and commercialization of civorebrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, outside of China and specific East and Southeast Asian countries. Travere will make an upfront payment of $112.5 million to Everest, with potential milestone payments reaching up to $1.03 billion for clinical, regulatory, and commercial achievements. Analysts are optimistic about Travere's financial prospects, forecasting profitability this year and noting the stock's current undervaluation.
